Pages that link to "Q33845996"
Jump to navigation
Jump to search
The following pages link to Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans (Q33845996):
Displaying 50 items.
- Is GLP-1 a hormone: Whether and When? (Q26749196) (← links)
- New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-catenin (Q26823824) (← links)
- Relationship between gut hormones and glucose homeostasis after bariatric surgery (Q27022123) (← links)
- Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation (Q28551517) (← links)
- Meal-anticipatory glucagon-like peptide-1 secretion in rats. (Q33634407) (← links)
- Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? (Q33789529) (← links)
- Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice (Q33800196) (← links)
- Glucagon-like peptide 1(GLP-1) in biology and pathology (Q34401791) (← links)
- Alpha cell function in health and disease: influence of glucagon-like peptide-1. (Q34560507) (← links)
- Expression of Human Globular Adiponectin-Glucagon-Like Peptide-1 Analog Fusion Protein and Its Assay of Glucose-Lowering Effect In Vivo (Q34648270) (← links)
- Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications. (Q35087846) (← links)
- What if Gut Hormones Aren't Really Hormones: DPP-4 Inhibition and Local Action of GLP-1 in the Gastrointestinal Tract (Q35110830) (← links)
- Glucose effectiveness in obese children: relation to degree of obesity and dysglycemia. (Q35207924) (← links)
- Enhancing Incretin Action for the Treatment of Type 2 Diabetes (Q35545683) (← links)
- β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity (Q35680897) (← links)
- Gut peptides in the treatment of diabetes mellitus (Q35688209) (← links)
- Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes (Q35744498) (← links)
- Beta cell function and its relation to insulin action in humans: a critical appraisal (Q35754764) (← links)
- Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal (Q35794504) (← links)
- Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice (Q35801801) (← links)
- The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management (Q36187070) (← links)
- Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches (Q36269671) (← links)
- Cardiovascular biology of the incretin system (Q36484283) (← links)
- Incretins and the development of type 2 diabetes (Q36560963) (← links)
- The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact? (Q36902183) (← links)
- Central control of body weight and appetite (Q36979763) (← links)
- Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects (Q37031078) (← links)
- Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides (Q37212333) (← links)
- Entero-insular axis and postprandial insulin differences in African American and European American children (Q37445535) (← links)
- Dipeptidyl peptidase in autoimmune pathophysiology (Q37853155) (← links)
- Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes (Q37857695) (← links)
- The structure and function of the glucagon-like peptide-1 receptor and its ligands (Q37939244) (← links)
- GLP‐1 based therapies: differential effects on fasting and postprandial glucose (Q37974712) (← links)
- Cardiovascular effects of incretin-based therapies (Q37977336) (← links)
- The therapeutic potential of GPR119 agonists for type 2 diabetes (Q37980173) (← links)
- The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists (Q38088195) (← links)
- Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions. (Q38264456) (← links)
- Glicentin-related pancreatic polypeptide inhibits glucose-stimulated insulin secretion from the isolated pancreas of adult male rats (Q38565583) (← links)
- Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives (Q38923365) (← links)
- GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products. (Q39063954) (← links)
- Advancing therapeutic discovery through phenotypic screening of the extracellular proteome using hydrodynamic intravascular injection (Q39117888) (← links)
- GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro (Q39168828) (← links)
- Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats (Q41809232) (← links)
- Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis (Q42022343) (← links)
- RETRACTED: Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment (Q42105494) (← links)
- Characterization of protein release from poly(ethylene glycol) hydrogels with crosslink density gradients (Q42824467) (← links)
- Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes (Q43194107) (← links)
- GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide (Q46637836) (← links)
- The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes (Q46872862) (← links)
- The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans (Q46887678) (← links)